CytoMed Therapeutics (NASDAQ:GDTC) Shares Up 6.5% – What’s Next?

Posted by ABMN Staff on Jun 13th, 2026

CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) traded up 6.5% on Friday . The stock traded as high as $1.14 and last traded at $1.14. 3,372 shares were traded during mid-day trading, a decline of 90% from the average session volume of 32,356 shares. The stock had previously closed at $1.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, CytoMed Therapeutics has an average rating of “Sell”.

Check Out Our Latest Analysis on CytoMed Therapeutics

CytoMed Therapeutics Trading Up 6.5%

The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. The company’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.17.

CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Company Profile

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.